Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2026-01-04 @ 5:49 PM
Study NCT ID:
NCT00000957
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HIV Infections | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Vaccines, Synthetic | View |
| None | Vaccinia Virus | View |
| None | Viral Vaccines | View |
| None | HIV-1 | View |
| None | Drug Evaluation | View |
| None | HIV Envelope Protein gp160 | View |
| None | Drug Administration Schedule | View |
| None | AIDS Vaccines | View |
| None | HIV Seronegativity | View |
| None | HIV Preventive Vaccine | View |